| Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection (NCT02253550) | Peter J. Ruane, M.D. | 2014-10-01 |
| Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C (NCT02250001) | Bristol-Myers Squibb | 2014-09-30 |
| Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease (NCT02207088) | AbbVie | 2014-09-23 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (NCT02243293) | AbbVie | 2014-09-19 |
| An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062) (NCT02105688) | Merck Sharp & Dohme LLC | 2014-09-02 |
| Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (NCT02202980) | Gilead Sciences | 2014-08-04 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection (NCT02243280) | AbbVie | 2014-08-01 |
| An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061) (NCT02105662) | Merck Sharp & Dohme LLC | 2014-06-03 |
| Effect of Camel Milk on Chronic Hepatitis C (NCT02216045) | Mashhad University of Medical Sciences | 2014-06-01 |
| Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059) (NCT02115321) | Merck Sharp & Dohme LLC | 2014-05-09 |
| Hepatocellular Carcinoma in HIV-infected Patients (NCT02785835) | Hospital Universitario de Valme | 2014-05-01 |
| Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies (NCT02293941) | TaiwanJ Pharmaceuticals Co., Ltd | 2014-05-01 |
| Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C (NCT02099604) | ANRS, Emerging Infectious Diseases | 2014-04-01 |
| A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection (NCT02068222) | AbbVie | 2014-04-01 |
| Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects (NCT02112942) | Merck Sharp & Dohme LLC | 2014-03-01 |
| Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients (NCT02282709) | Foundation for Liver Research | 2014-02-01 |
| A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) (NCT01995071) | AbbVie | 2013-11-01 |
| Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001) (NCT01974687) | Merck Sharp & Dohme LLC | 2013-10-31 |
| A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV (NCT01949168) | St Vincent's Hospital Melbourne | 2013-09-01 |
| Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy (NCT02788682) | Cairo University | 2013-09-01 |
| A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection (NCT01939197) | AbbVie | 2013-08-30 |
| Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin (NCT02508090) | Hoffmann-La Roche | 2013-08-02 |
| Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC) (NCT02628717) | Medical University of Vienna | 2013-07-01 |
| A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C (NCT01842451) | Vertex Pharmaceuticals Incorporated | 2013-06-01 |
| Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population (NCT01896609) | MinaPharm Pharmaceuticals | 2013-06-01 |
| Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C (NCT01903278) | Beijing Kawin Technology Share-Holding Co., Ltd. | 2013-06-01 |
| New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C (NCT01888900) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2013-05-01 |
| Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C (NCT01859962) | Presidio Pharmaceuticals, Inc. | 2013-05-01 |
| Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection (NCT01826981) | Gilead Sciences | 2013-04-01 |
| An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine (NCT01911845) | AbbVie | 2013-04-01 |
| A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment (NCT01817985) | Gilead Sciences | 2013-03-01 |
| A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C (NCT01790100) | Alios Biopharma Inc. | 2013-02-28 |
| Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C (NCT02123212) | National Opinion Research Center | 2013-02-01 |
| Clinical Pharmacology Study of MP-424 (NCT01766167) | Tanabe Pharma Corporation | 2013-02-01 |
| Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034) (NCT01590225) | Merck Sharp & Dohme LLC | 2013-01-28 |
| A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) (NCT01731301) | Liver Institute of Virginia | 2013-01-01 |
| A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study (NCT01609933) | AbbVie (prior sponsor, Abbott) | 2012-12-18 |
| Viral Kinetics in HCV Clearance in Subjects With Hemophilia (NCT01704521) | Kenneth Sherman | 2012-12-01 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C (NCT01726946) | Vertex Pharmaceuticals Incorporated | 2012-11-01 |
| Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048) (NCT01678131) | Merck Sharp & Dohme LLC | 2012-10-30 |
| A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus (NCT01724086) | Janssen R&D Ireland | 2012-10-01 |
| A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C (NCT01908335) | Beijing Kawin Technology Share-Holding Co., Ltd. | 2012-10-01 |
| Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C (NCT01649245) | MinaPharm Pharmaceuticals | 2012-08-01 |
| Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance (NCT01664845) | Kaohsiung Veterans General Hospital. | 2012-08-01 |
| Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated with Peginterferon Alpha-2a and Ribavirin (NCT01634919) | Seoul National University Boramae Hospital | 2012-07-01 |
| Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C (NCT01639547) | Chang Gung Memorial Hospital | 2012-07-01 |
| Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies (NCT01625338) | Gilead Sciences | 2012-06-01 |
| Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) (NCT01604850) | Gilead Sciences | 2012-06-01 |
| Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects (NCT01646489) | Santaris Pharma A/S | 2012-06-01 |
| Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection (NCT01641640) | Gilead Sciences | 2012-06-01 |
| Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms (NCT01641094) | Foundation for Liver Research | 2012-05-01 |
| Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022) (NCT01547312) | Merck Sharp & Dohme LLC | 2012-05-01 |
| Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c (NCT01655966) | Cairo University | 2012-05-01 |
| 24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C (NCT01517308) | Federico II University | 2012-05-01 |
| Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients (NCT01466192) | Tanabe Pharma Corporation | 2012-05-01 |
| Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients (NCT01581398) | Xiamen Amoytop Biotech Co., Ltd. | 2012-04-01 |
| Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients (NCT01525212) | Bristol-Myers Squibb | 2012-04-01 |
| Pharmacogenomics Study on IL28B Genetic Variants in Chinese Children With Hepatitis C Virus Infection (NCT01607021) | Beijing 302 Hospital | 2012-04-01 |
| Long Term Vitamin D Therapy in HCV Treated Patients (NCT01997203) | Dr. Nadia AbdelAaty AbdelKader | 2012-04-01 |
| An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1) (NCT01513941) | Janssen-Cilag International NV | 2012-04-01 |
| Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C (NCT02006823) | Duke University | 2012-03-01 |
| Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon (NCT01542788) | Gilead Sciences | 2012-03-01 |
| HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity (NCT01377909) | Bader, Ted, M.D. | 2012-03-01 |
| Keyhole Limpet Hemocyanin in Chronic Hepatitis C (NCT01509391) | Medical University of Graz | 2012-01-01 |
| BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C (NCT01623336) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2012-01-01 |
| A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects (NCT01511432) | Vertex Pharmaceuticals Incorporated | 2012-01-01 |
| Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy (NCT01405027) | Chronic Liver Disease Foundation | 2011-12-01 |
| Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications (NCT01455090) | Bristol-Myers Squibb | 2011-11-30 |
| Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects (NCT01459419) | Inspira Medical AB | 2011-11-01 |
| Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients (NCT01468584) | Tanabe Pharma Corporation | 2011-11-01 |
| Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC) (NCT01457937) | University of Modena and Reggio Emilia | 2011-11-01 |
| Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6 (NCT01433887) | Third Affiliated Hospital, Sun Yat-Sen University | 2011-11-01 |
| ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients (NCT01464827) | AbbVie (prior sponsor, Abbott) | 2011-10-01 |
| Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients (NCT01439776) | Hanyang University | 2011-09-01 |
| GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype (NCT01384383) | Gilead Sciences | 2011-08-01 |
| Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients? (NCT01151397) | Ziv Hospital | 2011-08-01 |
| The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients (NCT01413360) | Seoul National University Hospital | 2011-08-01 |
| Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C (NCT01402583) | Prof. Facchinetti Fabio | 2011-07-01 |
| Q-Trial in Patients With Hepatitis C (NCT01438320) | University of California, Los Angeles | 2011-07-01 |
| Pharmacogenomic Research in Korean Patients With Hepatitis C (NCT01453244) | Inje University | 2011-07-01 |
| Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care (NCT01359644) | Bristol-Myers Squibb | 2011-06-01 |
| A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism (NCT01441804) | Third Affiliated Hospital, Sun Yat-Sen University | 2011-05-01 |
| CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects (NCT01335711) | ChronTech Pharma AB | 2011-04-01 |
| Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects (NCT01314261) | AbbVie (prior sponsor, Abbott) | 2011-03-01 |
| Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital (NCT06922643) | Nanogen Pharmaceutical Biotechnology Joint Stock Company | 2011-03-01 |
| Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance (NCT01210404) | Pfizer | 2011-02-01 |
| Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir (NCT01577069) | Association HGE CHU Bordeaux Sud | 2011-02-01 |
| French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin (NCT01514890) | ANRS, Emerging Infectious Diseases | 2011-02-01 |
| Ribavirin Dose Optimization for the Treatment of Hepatitis C (NCT01289496) | Centre hospitalier de l'Université de Montréal (CHUM) | 2011-02-01 |
| Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy. (NCT01272310) | Sheba Medical Center | 2011-01-01 |
| A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients (NCT01263860) | Third Affiliated Hospital, Sun Yat-Sen University | 2010-12-01 |
| Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV) (NCT01276756) | Cairo University | 2010-12-01 |
| Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders (NCT01226446) | French National Agency for Research on AIDS and Viral Hepatitis | 2010-11-01 |
| Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography (NCT01360892) | Kindai University | 2010-09-01 |
| Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease (NCT01360879) | Kindai University | 2010-09-01 |
| Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C (NCT01140997) | Xiamen Amoytop Biotech Co., Ltd. | 2010-07-01 |
| Study of VX-985 in Subjects With Chronic Hepatitis C (NCT01144936) | Vertex Pharmaceuticals Incorporated | 2010-06-01 |
| A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002) (NCT01157104) | Merck Sharp & Dohme LLC | 2010-06-01 |
| Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4 (NCT01010646) | ANRS, Emerging Infectious Diseases | 2010-03-01 |
| EXtended Therapy in Hepatitis C Genotype 3 Infected Patients (NCT01095445) | University Health Network, Toronto | 2010-02-01 |